Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Chun Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2376-4703; OpenAlex author ID A5100373897; NIH RePORTER profile ID 1903519. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 7)
Trials
0
Grants
1
Labs led
1
Collaborators
28
Papers, trials and grants by year

2015: 1 paper · 2016: 1 paper · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: none · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: none · 2025: 1 paper · 2026: 1 paper, 1 grant

Papers 10

  1. Multiparametric MRI to Predict Response to Irreversible Electroporation Plus Anti-PD-1 Immunotherapy in Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1002/mrm.70188↗
  2. Re/99mTc Tricarbonyl Phenformin Complexes Targeting Mitochondria as Pancreatic Cancer Theranostics. Last author DOI 10.1021/acs.jmedchem.5c01760↗
  3. Simultaneous Delivery of Dual Inhibitors of DNA Damage Repair Sensitizes Pancreatic Cancer Response to Irreversible Electroporation. Co-author DOI 10.1021/acsnano.3c05009↗
  4. Local Release of TGF-β Inhibitor Modulates Tumor-Associated Neutrophils and Enhances Pancreatic Cancer Response to Combined Irreversible Electroporation and Im… Co-author DOI 10.1002/advs.202105240↗
  5. Incidental Findings of Coexisting Metastatic Pancreatic Cancer in Patients With Prostate Cancer on 18 F-Prostate-Specific Membrane Antigen PET/CT. First author DOI 10.1097/rlu.0000000000004338↗
  6. Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer. Last author DOI 10.1038/s41467-019-08782-1↗
  7. Simultaneous inhibition of hedgehog signaling and tumor proliferation remodels stroma and enhances pancreatic cancer therapy. Last author DOI 10.1016/j.biomaterials.2018.01.014↗
  8. Stromal Modulation Reverses Primary Resistance to Immune Checkpoint Blockade in Pancreatic Cancer. Last author DOI 10.1021/acsnano.8b02481↗
  9. Interventional Nanotheranostics of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.7150/thno.15122↗
  10. Cyclopamine-loaded core-cross-linked polymeric micelles enhance radiation response in pancreatic cancer and pancreatic stellate cells. Last author DOI 10.1021/mp500875f↗

Grants 1

  1. Development of irreversible electroporation-based rational combinations to potentiate the activity of cancer immunotherapy against pancreatic ductal adenocarci… R01CA258540↗

Closest collaborators

The 25 strongest of 28 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Y. Alan Wang · 1 shared grant, 2026 · strength 1.26
  2. Jun Zhao · 6 shared papers, 2015–2023 · strength 0.60
  3. Qizhen Cao · 2 shared papers, 2025–2026 · strength 0.53
  4. Yang Lü · 1 shared paper, 2022 · strength 0.33
  5. Huamin Wang · 2 shared papers, 2018–2025 · strength 0.30
  6. Hui Xu · 2 shared papers, 2022–2023 · strength 0.30
  7. Teng Huang · 2 shared papers, 2022–2023 · strength 0.30
  8. Xin Long · 2 shared papers, 2022–2023 · strength 0.30
  9. Marty D. Pagel · 1 shared paper, 2026 · strength 0.29
  10. Sanaz Javadi · 1 shared paper, 2026 · strength 0.29
  11. Chiyi Xiong · 1 shared paper, 2025 · strength 0.24
  12. Tao Yin · 1 shared paper, 2023 · strength 0.16
  13. Tianan Jiang · 1 shared paper, 2023 · strength 0.16
  14. Jian Shen · 1 shared paper, 2022 · strength 0.14
  15. Huiming Peng · 1 shared paper, 2022 · strength 0.14
  16. Heshui Wu · 1 shared paper, 2022 · strength 0.14
  17. Junjie Li · 1 shared paper, 2016 · strength 0.08
  18. Ying Yuan · 1 shared paper, 2018 · strength 0.08
  19. David R Piwnica-Worms · 1 shared paper, 2018 · strength 0.07
  20. Stephen E. Ullrich · 1 shared paper, 2018 · strength 0.07
  21. Ya’an Kang · 1 shared paper, 2018 · strength 0.07
  22. Qian Huang · 1 shared paper, 2018 · strength 0.07
  23. Ying Ma · 1 shared paper, 2018 · strength 0.07
  24. Jason B. Fleming · 1 shared paper, 2018 · strength 0.07
  25. Anirban Maitra · 1 shared paper, 2018 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.